#ESMO18: Crowned with a breakthrough title, Clovis takes an early lead as it races for a fast OK for Rubraca in prostate cancer
MUNICH — With Lynparza from AstraZeneca and Merck expanding on a big lead for ovarian and breast cancer, Clovis Oncology $CLVS is mapping a separate route in prostate cancer for their PARP rival Rubraca that may pay off handsomely.
The Boulder, CO-based biotech turned up in Munich today to unveil an early look at Phase II data from their TRITON2 study, with a 44% confirmed objective response rate in 25 second-line, RECIST-evaluable patients with a BRCA1/2 alteration. Researchers also claimed a 51% PSA response rate in 45 prostate cancer patients as well as some biomarker reactions that they count as a promising sign for the future data to come out of the program.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.